Conclusion
Patients with intracranial PNET should be managed as per EWSR1 gene rearrangement report. If rearrangement is detected, the treatment will be planned on the lines of peripheral PNET / Ewing’s sarcoma, including focal RT and chemotherapy as per EFT protocol. If rearrangement is not detected, the line of management will be as per embryonal tumor, i.e., like high-risk medulloblastoma, necessitating CSI with tumor bed boost, with concurrent chemotherapy, followed by adjuvant chemotherapy. Vincristine can be used in concurrent setting instead of carboplatin.
References :
1. Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TSY, et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012 Aug;13(8):838–48. 2. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro-Oncol. 2019 Nov 1;21(Suppl 5):v1–100. 3. Kovar H. Ewing’s sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr Opin Oncol. 1998 Jul;10(4):334–42. 4. McNeil DE, Coté TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Med Pediatr Oncol. 2002;39(3):190–4. 5. Chen J, Jiang Q, Zhang Y, Yu Y, Zheng Y, Chen J, et al. Clinical Features and Long-Term Outcome of Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases from a Single Institution. World Neurosurg. 2019 Feb;122:e1606–14. 6. Primary Intracranial pPNET/Ewing Sarcoma: Diagnosis, Management, and Prognostic Factors Dilemma–A Systematic Review of the Literature. World Neurosurg. 2018 Jul 1;115:346–56. 7. Folpe AL, Hill CE, Parham DM, O’Shea PA, Weiss SW. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing’s sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000 Dec;24(12):1657–62. 8. VandenHeuvel KA, Al-Rohil RN, Stevenson ME, Qian J, Gross NL, McNall-Knapp R, et al. Primary intracranial Ewing’s sarcoma with unusual features. Int J Clin Exp Pathol. 2015 Jan 1;8(1):260–74. 9. Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, Perry A. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol Off J U S Can Acad Pathol Inc. 2006 Jan;19(1):1–8. 10. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 1983 Jan;42(1):1–15. 11. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24;415(6870):436–42. 12. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 2016 Feb 25;164(5):1060–72. 13. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). 2016 Jun;131(6):803–20. 14. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021 Aug 1;23(8):1231–51. 15. Dai AI, Backstrom JW, Burger PC, Duffner PK. Supratentorial primitive neuroectodermal tumors of infancy: clinical and radiologic findings. Pediatr Neurol. 2003 Nov;29(5):430–4. 16. Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, et al. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro-Oncol. 2011 Aug;13(8):866–79. 17. Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Childrens Cancer Group randomized trial. J Clin Oncol. 1995 Jul;13(7):1687–96. 18. Timmermann B, Kortmann RD, Kühl J, Meisner C, Dieckmann K, Pietsch T, et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol Off J Am Soc Clin Oncol. 2002 Feb 1;20(3):842–9. 19. Packer RJ, Macdonald T, Vezina G, Keating R, Santi M. Medulloblastoma and primitive neuroectodermal tumors. Handb Clin Neurol. 2012;105:529–48. 20. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer. 2000 May 1;88(9):2189–93. 21. De Braganca KC, Packer RJ. Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). Curr Treat Options Neurol. 2013 Oct 1;15(5):593–606. 22. Ho CY, VandenBussche CJ, Huppman AR, Chaudhry R, Ali SZ. Cytomorphologic and clinicoradiologic analysis of primary nonhematologic central nervous system tumors with positive cerebrospinal fluid. Cancer Cytopathol. 2015;123(2):123–35. 23. Stensvold E, Krossnes BK, Lundar T, Due-Tønnessen BJ, Frič R, Due-Tønnessen P, et al. Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) – a retrospective analysis spanning 40 years of treatment. Acta Oncol. 2017 Jun 3;56(5):698–705. 24. Rana K, Wadhwa V, Bhargava EK, Batra V, Mandal S. Ewing’s Sarcoma Multifocal Metastases to Temporal and Occipital Bone: A Rare Presentation. J Clin Diagn Res JCDR. 2015 Jun;9(6):MD04–5. 25. Parasuraman S, Langston J, Rao BN, Poquette CA, Jenkins JJ, Merchant T, et al. Brain metastases in pediatric Ewing sarcoma and rhabdomyosarcoma: the St. Jude Children’s Research Hospital experience. J Pediatr Hematol Oncol. 1999;21(5):370–7. 26. Koç ZP, Kara PÖ, Dağtekin A. Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography. CNS Oncol. 2018 Apr 30;7(2):CNS12. 27. Hueser CN, Nguyen NC, Osman M, Havlioglu N, Patel AJ. Extrapulmonary small cell sarcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World J Surg Oncol. 2008 Sep 25;6(1):102. 28. Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery. 1996 Feb;38(2):265–71. 29. Hwang EI, Kool M, Burger PC, Capper D, Chavez L, Brabetz S, et al. Extensive Molecular and Clinical Heterogeneity in Patients with Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report from the Children’s Oncology Group Randomized ACNS0332 Trial. J Clin Oncol. 2018 Dec 1;36(34):3388–95. 30. Biswas S, Burke A, Cherian S, Williams D, Nicholson J, Horan G, et al. Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation? Pediatr Blood Cancer. 2009 Jul;52(7):796–803. 31. Timmermann B, Kortmann RD, Kühl J, Rutkowski S, Meisner C, Pietsch T, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Apr 1;24(10):1554–60. 32. Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatr Blood Cancer. 2008;50(2):312–8. 33. Massimino M, Gandola L, Biassoni V, Spreafico F, Schiavello E, Poggi G, et al. Evolving of therapeutic strategies for CNS-PNET. Pediatr Blood Cancer. 2013;60(12):2031–5. 34. Chintagumpala M, Hassall T, Palmer S, Ashley D, Wallace D, Kasow K, et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro-Oncol. 2009 Feb 1;11(1):33–40.
Figures :